Dr Selina Chavda details
Telephone:
Location:
- University College Hospital
GMC/GDC number:
7090073
Professional background
Dr Selina Chavda is a consultant haematologist with specialist interest in multiple myeloma and phase I clinical trials. She is a successful clinical academic and has completed an PhD investigating the role of autophagy in proteasome inhibitor resistance in multiple myeloma.
She undertook her PhD in Professor Kwee Yong’s laboratory and was funded by the Medical Research Council Fellowship. She has published 27 peer reviewed publications in high impact factor journals. Dr Chavda also works in the phase I clinical research facility and is the PI on a number of phase I studies. She was awarded a prestigious EHA scholarship on the CRTH programme in management and running of clinical trials.
She is passionate about improving access to MM therapies and participation in clinical trials and is the co-lead for the UK Myeloma Research Alliance Equality, Diversity and Inclusion (EDI) Sub-committee, and is the named early career researcher for the EDI group.
At UCLH, she is also the lead for haematology postgraduate medical education. Dr Chavda completed her undergraduate training at UCL and undertook her training in tertiary centres including the Royal Marsden Hospital, St George’s Hospital and UCLH.
Specialties
Research interests
- Drug resistance mechanisms
- Small molecule inhibitors
- Bispecific T cell engagers
- CAR-T therapy
Languages spoken
Gujurati
Publications
- Popat R, Chavda SJ. Daratumumab combinations for patients with newly diagnosed and relapsed multiple myeloma. Lancet Haematology 2023: 10; e788-e789. PMID: 37793762
- Cowan A, Ferrari F, Freeman SS, Redd R, El-Khoury H, Perry J, Patel V, Kaur P, Barr H, Lee DJ, Lightbody E, Downey K, Argyelan D, Theodorakakou F, Fotiou D, Liacos CI, Kanellias N, Chavda SJ, Ainley L, Sandecka V, Pospisilova L, Minarik J, Jungova A, Radocha J, Spicka I, Nadeem O, Yong K, Hajek R, Kastritis E, Marinac CR, Dimopoulos MA, Get G, Trippa L, Ghobrial IM. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study. Lancet Haematology 2023: 10; e203-e212. PMID: 36858677
- Leng H, Zhang H, Li L, Zhang S, Wang Y, Chavda SJ, Galas-Filipowicz D, Lou H, Ersek A, Morris EV, Sezgin E, Lee YH, Li Y, Lechuga-Vieco AV, Tian M, Mi JQ, Yong K, Zhong Q, Edwards CM, Simon AK, Horwood NJ. Modulating glycosphingolipid metabolism and autophagy improved outcomes in pre-clinical models of myeloma bone disease. Nature Communications 2022: 13(1); 7868. PMID: 35660101
- Yong K, Wilson W, de Tute RM, Camilleri M, Ramasamy K, Streetly M, Sive J, Bygrave CA, Benjamin R, Chapman M, Chavda SJ, Phillips EH, Del Mar Cuadrado M, Pang G, Jenner R, Dadaga T, Kamora S, Cavenagh J, Clifton-Hadley L, Owen RG, Popat R. Upfront autologous haematopietic stem cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial. Lancet Haematology 2023: 10; e93-e106. PMID: 36529145
- Gooding S, Ansari-Pour N, Kazeroun MH, Karagoz K, Polonskaia A, Angulo Salazar M, Fitzsimons E, Sirinukunwattana K, Chavda SJ, Ortiz Estevez M, Towfic F, Flynt E, Pierceall W, Royston D, Yong KL, Ramasamy K, Vyas P, Thakurta A. Loss of COP9-Signalosome genes at 2q37 is associated with IMiD Agent resistance in multiple myeloma. Blood 2022; Jul 19. Online ahead of print. PMID: 35853156
- Bustoros M, Anand S, Sklavenitis-Pistofidis R, Redd R, Boyle EM, Zhitomirsky B, Dunford AJ, Tai YT, Chavda SJ, Boehner C, Neuse CJ, Rahmat M, Dutta A, Casneuf T, Verona R, Kastritis E, Trippa L, Stewart C, Walker BA, Davies FE, Dimopoulos MA, Bergsagel PL, Yong K, Morgan GJ, Aguet F, Getz G, Ghobrial IM. Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes. Nature Communications 2022; 13 (1): 3449. PMID: 35705541
- Ainley L, Camilleri M, Chavda SJ, McMillan A, Lee L, Popat R, Sillito F, Yong K. Applying current smouldering myeloma risk models to a UK single-centre cohort and clinical features at progression. British Journal of Haematology 2022: 196 (6): e63 - e66. PMID: 34812509.
- Chan WY, Howells L, Wilson W, Sanchez E, Ainley L, Chavda SJ, Dowling E, Correia N, Lecat CSY, McMillan A, Wisniowski B, Mahmood S, Papanikolaou X, Lee L, Sive J, Kyriakou C, Wechalekar A, Popat R, Rabin N, Nastouli E, Yong KL, Xu K. Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV-19 COVID-19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors. British Journal of Haematology 2022: 196 (3): e21-e26. PMID: 34632575
- Richards H, Chavda SJ, Wilson W, Camilleri M, Cohen O, Horder J, Newrick F, Papanikolaou X, Sive J, Lee L, Popat R, Wechalekar A, Kyriakou C, Yong K, Rabin N. Salvage second autologous stem cell transplant for relapsed multiple myeloma in the novel agent era benefits a subset of patients: single-centre UK experience. Leukaemia and Lymphoma 2021: 62 (14): 3544-47. PMID: 34348069
- Chan WY, Sanchez E, Chavda SJ, Lecat CSY, Ainley L, Xu K, Wisniowski B, Mahmood S, Papanikolaou X, Kyriakou C, Sive J, Wechalekar A, Popat R, Rabin N, Lee L, Nastouli E, Yong KL. Development of antibody response to SARS-CoV-2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy. British Journal of Haematology 2021; 194 (5): 857-61. PMID: 34323287
- Lee L, Alrasheed N, Khandelwal G, Fitzsimons E, Richards H, Wilson W, Chavda SJ, Henry J, Conde L, de Massy MR, Chin M, Galas-Filipowicz D, Herrero J, Chain B, Quezada SA, Yong K. Increased immune-regulatory receptor expression on effector T cells as early indicators of relapse following autologous stem cell transplantation for multiple myeloma. Frontiers in Immunology 2021; 12: 618610. PMID: 33717112
- Camilleri M, Cuadrado M, Phillips E, Wilson W, Jenner R, Pang G, Kamora S, Streetly M, Popat R, Bygrave C, Owen R, Cavenagh J, Chapman M, Sive J, Eccersley L, Sheaff M, Benjamin R, Ramasamy K, Cook G, Virchis A, Chavda SJ, Clifton-Hadley L, Scully MA, Yong K. Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study. British Journal of Haematology 2021; 193: 750-760. PMID: 33650100
- Ainley L, Chavda SJ, Counsell N, Cheesman S, Newrick F, Horder J, Kyriakou C, Papanikolaou X, Sive J, Lee L, Wechalekar A, Mehta A, Popat R, Rabin N, Yong K. DT-PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation. British Journal of Haematology 2021: 192; e73-e77. PMID: 33236352
- Fox TA, Troy-Barnes E, Kirkwood AA, Chan WY, Day J, Chavda SJ, Kumar EA, David K, Tomkins O, Sanchez E, Scully M, Khwaja A, Lambert J, Singer M, Roddie C, Morris EC, Yong KL, Thomson KJ, Ardeshna KM. Clinical outcomes and risk factors for severe COVID-19 infection in patients with haematological disorders receiving chemo- or immunotherapy. British Journal of Haematology 2020: 191; 194-206. PMID: 32678948
- Chavda SJ, Pocock R, Cheesman S, Lee KM, Dowling E, Marks DJB, Kyriakou C, Lee L, Sive J, Wechalekar A, Rabin N, Yong K, Popat R. Association of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendations. British Journal of Haematology 2020: 190; e312-e316. PMID: 32535901
- Bustoros M, Sklavenitis-Pistofidis R, Park J, Redd R, Zhiromirsky B, Dunford AJ, Salem K, Tai YT, Anand S, Mouhieddine TH, Chavda SJ, Boehner C, Elagina L, Neuse CJ, Cha J, Rahmat M, Taylor-Weiner A, Van Allen E, Kumar S, Kastritis E, Leshchiner I, Morgan EA, Laubach J, Casneuf T, Richardson P, Munshi NC, Anderson KC, Trippa L, Aguet F, Stewart C, Dimopoulos MA, Yong K, Bergsagel L, Manier S, Getz G, Ghobrial IM. Genomic profiling of smoldering multiple mylemona indentifies patients at high risk of disease progression. Journal of Clinical Oncology 2020: 38; 2380-2389. PMID: 32442065
- Alrasheed N, Lee L, Ghorani E, Henry JY, Conde L, Chin M, Galas-Filipowicz D, Furness AJS, Chavda SJ, Richards J, De-Silva D, Cohen OC, Patel D, Brooks A, Rodriguez-Justo M, Pule M, Herrero J, Quezada SA, Yong KL. Marrow infiltrating regulatory T cells correlate with the presence of dysfunctional CD4+ PD-1+ cells and inferior survival in patients with newly diagnosed multiple myeloma. Clinical Cancer Research 2020: 26; 3443-3454. PMID: 32220887
- Chavda SJ, Maciocia P, Mesiri P, Counsell N, Kothari J. Bird A, Mariner C, Chew A, Clesham K, Moore S, Percy L, Rismani A, D’Sa S, Rabin N, Popat R, Yong K. A new prognostic model for patients relapsing from upfront autologous transplantation for myeloma based on ISS and PFS1. British Journal of Haematology 2019: 185; 350-3. PMID: 29984833
- Chin M, Sive JI, Allen C, Roddie C, Chavda SJ, Smith D, Blombery P, Jones K, Ryland GL, Popat R, Rismani A, D’Sa S, Rabin N, Gale RE, Yong KL. Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival. Blood Cancer Journal 2017; 7(9): e610. PMID: 29016571
- Chavda SJ, Yong K. Multiple myeloma: what you need to know. British Journal of Hospital Medicine 2017; 78: C21-7. PMID: 28165783